CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...